{
  "docId": "019de076-4eee-72eb-9f75-bef42550a1c1",
  "docSlug": "3c2d586ebe2940705b3e5004470d76e3",
  "documentTitle": "Kymera | Investor Presentation Deck | 41 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 41,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "TPD = Targeted Protein Degradation. UD = Undrugged, ID = Inadequately drugged.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4eee-72eb-9f75-bef42550a1c1/5",
  "deckHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1",
  "deckJsonHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1.json",
  "deckAnchorHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.29,
        "x": 0.65,
        "y": 0.68
      },
      "kind": "chart",
      "text": "Clinical translation line chart",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b601c6bb-6693-4a15-89e4-06c1dd1839e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.29,
        "x": 0.65,
        "y": 0.34
      },
      "kind": "chart",
      "text": "Fidelity of translation of PK, PD and safety in 3 programs in immunology and oncology",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8f38a9db-4530-4759-ba7a-4448ab20bbd1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.22,
        "x": 0.39,
        "y": 0.45
      },
      "kind": "image",
      "text": "E3 Ligase and Glue illustrations",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ad55839-953e-413d-b1dc-2c9076d1c3b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.24,
        "x": 0.08,
        "y": 0.45
      },
      "kind": "image",
      "text": "Molecular structures",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f0e5766a-dd2e-49df-b42a-f84b065c5c04",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.88,
        "x": 0.06,
        "y": 0.21
      },
      "kind": "list",
      "text": "TARGET SELECTION; PLATFORM; CLINICAL TRANSLATION",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "57575cd1-ae54-466b-be0d-887581984b04",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.85,
        "w": 0.28,
        "x": 0.06,
        "y": 0.34
      },
      "kind": "paragraph",
      "text": "Undrugged (UD) or inadequately drugged (ID) targets; Strong genetic validation within clinically validated pathway",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41bfa735-8b01-4da1-8276-e758b256e494",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.85,
        "w": 0.28,
        "x": 0.36,
        "y": 0.34
      },
      "kind": "paragraph",
      "text": "Significantly differentiated investments; Tissue-selective E3 Ligases; New Molecular Glue Approach; Enabling a whole new generation of clinical programs; Novel strategy to address undrugged/unligandable targets",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d656a812-c26c-4036-99a5-d3b2afa3e0a2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.58,
        "x": 0.21,
        "y": 0.04
      },
      "kind": "title",
      "text": "Kymera: A Differentiated Approach to TPD",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbe89de2-807b-4bd9-a153-fa2496008d77",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 5,
      "beatId": "ca1de62b-2499-4880-b396-8fc4f8f1e29b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Kymera's platform and pipeline are presented as a differentiated approach to TPD.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}